Regeneron bids for 23andMe for a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

Genetics company 23andMe is expected to be purchased by Regeneron Pharmaceuticals, according to announcements shared by both ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

It also aligns with a strategy that 23andMe had been pursuing for years. The Regeneron Biotechnology company logo is seen displayed on a smartphone. (Igor Golovniov/SOPA Images/LightRocket via ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data ...

Genetic testing company 23andMe had 15 million consumers who turned to them to learn more about their ancestry and understand their disposition to diseases.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...